Kang D, Yang M, Cheong H, Park C
Commun Biol. 2024; 7(1):1425.
PMID: 39487330
PMC: 11530643.
DOI: 10.1038/s42003-024-07133-1.
Lucas N, Neal C, Hsu B, Wright P
Cureus. 2024; 16(5):e61168.
PMID: 38933637
PMC: 11202094.
DOI: 10.7759/cureus.61168.
Li C, Zhang J, Wu Q, Kumar A, Pan G, Kelvin D
Mol Cancer Ther. 2023; 22(3):306-316.
PMID: 36622760
PMC: 9978883.
DOI: 10.1158/1535-7163.MCT-22-0159.
Wasmuth E, Vanden Broeck A, LaClair J, Hoover E, Lawrence K, Paknejad N
Mol Cell. 2022; 82(11):2021-2031.e5.
PMID: 35447082
PMC: 9177810.
DOI: 10.1016/j.molcel.2022.03.035.
Lorenzin F, Demichelis F
Cancers (Basel). 2022; 14(5).
PMID: 35267426
PMC: 8909394.
DOI: 10.3390/cancers14051118.
EZH2-induced lysine K362 methylation enhances TMPRSS2-ERG oncogenic activity in prostate cancer.
Zoma M, Curti L, Shinde D, Albino D, Mitra A, Sgrignani J
Nat Commun. 2021; 12(1):4147.
PMID: 34230470
PMC: 8260656.
DOI: 10.1038/s41467-021-24380-6.
The FLI portion of EWS/FLI contributes a transcriptional regulatory function that is distinct and separable from its DNA-binding function in Ewing sarcoma.
Boone M, Taslim C, Crow J, Selich-Anderson J, Byrum A, Showpnil I
Oncogene. 2021; 40(29):4759-4769.
PMID: 34145397
PMC: 8298202.
DOI: 10.1038/s41388-021-01876-5.
Allosteric interference in oncogenic FLI1 and ERG transactions by mithramycins.
Hou C, Mandal A, Rohr J, Tsodikov O
Structure. 2020; 29(5):404-412.e4.
PMID: 33275876
PMC: 8106648.
DOI: 10.1016/j.str.2020.11.012.
Structural Insight into the DNA Binding Function of Transcription Factor ERF.
Hou C, McCown C, Ivanov D, Tsodikov O
Biochemistry. 2020; .
PMID: 33175491
PMC: 8110599.
DOI: 10.1021/acs.biochem.0c00774.
The human CRY1 tail controls circadian timing by regulating its association with CLOCK:BMAL1.
Parico G, Perez I, Fribourgh J, Hernandez B, Lee H, Partch C
Proc Natl Acad Sci U S A. 2020; 117(45):27971-27979.
PMID: 33106415
PMC: 7668087.
DOI: 10.1073/pnas.1920653117.
Asymmetric Conservation within Pairs of Co-Occurred Motifs Mediates Weak Direct Binding of Transcription Factors in ChIP-Seq Data.
Levitsky V, Oshchepkov D, Zemlyanskaya E, Merkulova T
Int J Mol Sci. 2020; 21(17).
PMID: 32825662
PMC: 7504069.
DOI: 10.3390/ijms21176023.
How Computational Chemistry and Drug Delivery Techniques Can Support the Development of New Anticancer Drugs.
Garofalo M, Grazioso G, Cavalli A, Sgrignani J
Molecules. 2020; 25(7).
PMID: 32290224
PMC: 7180704.
DOI: 10.3390/molecules25071756.
Modulation of androgen receptor DNA binding activity through direct interaction with the ETS transcription factor ERG.
Wasmuth E, Hoover E, Antar A, Klinge S, Chen Y, Sawyers C
Proc Natl Acad Sci U S A. 2020; 117(15):8584-8592.
PMID: 32220959
PMC: 7165421.
DOI: 10.1073/pnas.1922159117.
Electrostatic repulsion causes anticooperative DNA binding between tumor suppressor ETS transcription factors and JUN-FOS at composite DNA sites.
Madison B, Clark K, Bhachech N, Hollenhorst P, Graves B, Currie S
J Biol Chem. 2018; 293(48):18624-18635.
PMID: 30315111
PMC: 6290139.
DOI: 10.1074/jbc.RA118.003352.
Comparative structure analysis of the ETSi domain of ERG3 and its complex with the E74 promoter DNA sequence.
Sharma R, Gangwar S, Saxena A
Acta Crystallogr F Struct Biol Commun. 2018; 74(Pt 10):656-663.
PMID: 30279318
PMC: 6168766.
DOI: 10.1107/S2053230X1801110X.
Structural basis for genome wide recognition of 5-bp GC motifs by SMAD transcription factors.
Martin-Malpartida P, Batet M, Kaczmarska Z, Freier R, Gomes T, Aragon E
Nat Commun. 2017; 8(1):2070.
PMID: 29234012
PMC: 5727232.
DOI: 10.1038/s41467-017-02054-6.
ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis.
Bose R, Karthaus W, Armenia J, Abida W, Iaquinta P, Zhang Z
Nature. 2017; 546(7660):671-675.
PMID: 28614298
PMC: 5576182.
DOI: 10.1038/nature22820.
Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer.
Butler M, Roshan-Moniri M, Hsing M, Lau D, Kim A, Yen P
Oncotarget. 2017; 8(26):42438-42454.
PMID: 28465491
PMC: 5522078.
DOI: 10.18632/oncotarget.17124.
Allosteric Autoinhibition Pathway in Transcription Factor ERG: Dynamics Network and Mutant Experimental Evaluations.
Ye W, Qian T, Liu H, Luo R, Chen H
J Chem Inf Model. 2017; 57(5):1153-1165.
PMID: 28425706
PMC: 5730271.
DOI: 10.1021/acs.jcim.7b00073.
Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer.
Wang X, Qiao Y, Asangani I, Ateeq B, Poliakov A, Cieslik M
Cancer Cell. 2017; 31(4):532-548.e7.
PMID: 28344039
PMC: 5443258.
DOI: 10.1016/j.ccell.2017.02.017.